Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer

This publication has 11 references indexed in Scilit:

• Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously
  British Journal of Cancer, 1996
• Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients
  Annals of Oncology, 1996
• High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer
  Cancer, 1994
• Induction of Multidrug Resistance in Human Cells by Transient Exposure to Different Chemotherapeutic Drugs
  JNCI Journal of the National Cancer Institute, 1993
• Dose intensity as a therapeutic strategy in breast cancer
  Breast Cancer Research and Treatment, 1991
• A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients
  Cancer Chemotherapy and Pharmacology, 1991
• Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.
  Journal of Clinical Oncology, 1990
• Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
  Journal of Clinical Oncology, 1988
• AUTOLOGOUS BONE MARROW RESCUE IS UNNECESSARY AFTER VERY-HIGH-DOSE CYCLOPHOSPHAMIDE
  The Lancet, 1983
• Dose: A critical factor in cancer chemotherapy
  The American Journal of Medicine, 1980